{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T21:01:02Z","timestamp":1780174862764,"version":"3.54.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470848"],"award-info":[{"award-number":["81470848"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["201903010099"],"award-info":[{"award-number":["201903010099"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbadis.2026.168237","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:49:09Z","timestamp":1775494149000},"page":"168237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic GAL1 deficiency alleviates steatosis via WWP2-mediated PARP1 degradation and activation of the SIRT1\u2013CPT1A pathway"],"prefix":"10.1016","volume":"1872","author":[{"given":"Yuqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bbadis.2026.168237_bb0005","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.bbadis.2026.168237_bb0010","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2026.168237_bb0020","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000719","article-title":"Galectins: structure, function and therapeutic potential","volume":"10","author":"Yang","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168237_bb0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ctrv.2013.07.007","article-title":"Unraveling galectin-1 as a novel therapeutic target for cancer","volume":"40","author":"Astorgues-Xerri","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168237_bb0030","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.208884","article-title":"Galectins at a glance","volume":"131","author":"Johannes","year":"2018","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1535-6108(04)00024-8","article-title":"Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege","volume":"5","author":"Rubinstein","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168237_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1096\/fj.201800555RR","article-title":"Galectin-1 is a new fibrosis protein in type 1 and type 2 diabetes","volume":"33","author":"Al-Obaidi","year":"2019","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168237_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12100930","article-title":"Galectin-1 in obesity and type 2 diabetes","volume":"12","author":"Fryk","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.bbadis.2026.168237_bb0050","first-page":"207","article-title":"Versatile effects of galectin-1 protein-containing lipid bilayer coating for cardiovascular applications","volume":"42","author":"Hasan","year":"2024","journal-title":"Bioact. Mater."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168237_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm7322","article-title":"Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm","volume":"8","author":"Rold\u00e1n-Montero","year":"2022","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168237_bb0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/biomedicines13020425","article-title":"Feasibility of serum Galectin-1 as a diagnostic biomarker for metabolic dysfunction-associated steatotic liver disease: a study on a segment of the Chinese population using convenience sampling","volume":"13","author":"Zeng","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbadis.2026.168237_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.peptides.2017.07.009","article-title":"Serum galectin-1 levels are positively correlated with body fat and negatively with fasting glucose in obese children","volume":"95","author":"Acar","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.bbadis.2026.168237_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2016.02.018","article-title":"Pharmacological inhibition of galectin-1 by lactulose alleviates weight gain in diet-induced obese rats","volume":"148","author":"Mukherjee","year":"2016","journal-title":"Life Sci."},{"issue":"14","key":"10.1016\/j.bbadis.2026.168237_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150461","article-title":"A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis","volume":"7","author":"Lluch","year":"2022","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168237_bb0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1101\/gad.291518.116","article-title":"PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes","volume":"31","author":"Gupte","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbadis.2026.168237_bb0085","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/ncomms3240","article-title":"A systematic analysis of the PARP protein family identifies new functions critical for cell physiology","volume":"4","author":"Vyas","year":"2013","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168237_bb0090","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/hep.26763","article-title":"Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis","volume":"59","author":"Mukhopadhyay","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.10.023","article-title":"PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis","volume":"66","author":"Mukhopadhyay","year":"2017","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168237_bb0100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jhep.2016.11.020","article-title":"PARP1-mediated PPAR\u03b1 poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease","volume":"66","author":"Huang","year":"2017","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168237_bb0105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","article-title":"PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation","volume":"13","author":"Bai","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbadis.2026.168237_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.01.014","article-title":"The taming of PARP1 and its impact on NAD(+) metabolism","volume":"38","author":"Hurtado-Bag\u00e8s","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bbadis.2026.168237_bb0115","doi-asserted-by":"crossref","first-page":"101117","DOI":"10.1016\/j.plipres.2021.101117","article-title":"PARPs in lipid metabolism and related diseases","volume":"84","author":"Sz\u00e1nt\u00f3","year":"2021","journal-title":"Prog. Lipid Res."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168237_bb0120","first-page":"418","article-title":"Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (version 2024)","volume":"32","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"4","key":"10.1016\/j.bbadis.2026.168237_bb0125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2017.11.040","article-title":"Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice","volume":"68","author":"Xu","year":"2018","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168237_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/nu9101072","article-title":"Animal models of nonalcoholic fatty liver disease-a starter\u2019s guide","volume":"9","author":"Van Herck","year":"2017","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168237_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41419-020-03367-z","article-title":"Galectin-1 accelerates high-fat diet-induced obesity by activation of peroxisome proliferator-activated receptor gamma (PPAR\u03b3) in mice","volume":"12","author":"Baek","year":"2021","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168237_bb0140","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/s41418-020-0523-2","article-title":"Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling","volume":"27","author":"Zhang","year":"2020","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0145","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/cr.2009.136","article-title":"Wwp2 mediates Oct4 ubiquitination and its own auto-ubiquitination in a dosage-dependent manner","volume":"20","author":"Liao","year":"2010","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.molcel.2017.03.020","article-title":"A tunable brake for HECT ubiquitin ligases","volume":"66","author":"Chen","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168237_bb0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41421-023-00555-x","article-title":"BAF155 promotes cardiac hypertrophy and fibrosis through inhibition of WWP2-mediated PARP1 ubiquitination","volume":"9","author":"Zhang","year":"2023","journal-title":"Cell Discov."},{"issue":"22","key":"10.1016\/j.bbadis.2026.168237_bb0160","doi-asserted-by":"crossref","first-page":"31738","DOI":"10.18632\/oncotarget.9194","article-title":"Galectin-1 is essential for efficient liver regeneration following hepatectomy","volume":"7","author":"Potikha","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.bbadis.2026.168237_bb0165","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin. Sci. (Lond.)"},{"issue":"8","key":"10.1016\/j.bbadis.2026.168237_bb0170","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.bbadis.2026.168237_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168237_bb0180","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"issue":"7731","key":"10.1016\/j.bbadis.2026.168237_bb0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-018-0645-6","article-title":"De novo NAD(+) synthesis enhances mitochondrial function and improves health","volume":"563","author":"Katsyuba","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2026.168237_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jnutbio.2016.03.009","article-title":"A conjugated fatty acid present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD(+)\/NADH ratio and activating PPAR\u03b1, AMPK and SIRT1 signaling pathway","volume":"33","author":"Chen","year":"2016","journal-title":"J. Nutr. Biochem."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168237_bb0195","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1113\/JP280908","article-title":"NAD(+) and NAFLD - caution, causality and careful optimism","volume":"600","author":"Dall","year":"2022","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168237_bb0200","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.28245","article-title":"Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice","volume":"63","author":"Gariani","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bbadis.2026.168237_bb0205","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity","volume":"15","author":"Cant\u00f3","year":"2012","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168237_bb0210","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ptr.6417","article-title":"Puerarin protects against high-fat high-sucrose diet-induced non-alcoholic fatty liver disease by modulating PARP-1\/PI3K\/AKT signaling pathway and facilitating mitochondrial homeostasis","volume":"33","author":"Wang","year":"2019","journal-title":"Phytother. Res."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168237_bb0215","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41420-022-01209-9","article-title":"The role of E3 ubiquitin ligase WWP2 and the regulation of PARP1 by ubiquitinated degradation in acute lymphoblastic leukemia","volume":"8","author":"Lu","year":"2022","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neo.2014.03.002","article-title":"The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells","volume":"16","author":"Piao","year":"2014","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168237_bb0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.bbadis.2026.168237_bb0230","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1093\/nar\/gkz545","article-title":"MORC2 regulates DNA damage response through a PARP1-dependent pathway","volume":"47","author":"Zhang","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168237_bb0235","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cell.2016.03.003","article-title":"Types of ubiquitin ligases","volume":"165","author":"Morreale","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168237_bb0240","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-023-01439-y","article-title":"Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168237_bb0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tem.2013.12.001","article-title":"SIRT1 and other sirtuins in metabolism","volume":"25","author":"Chang","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168237_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/biom12081079","article-title":"Progress in nonalcoholic fatty liver disease: SIRT family regulates mitochondrial biogenesis","volume":"12","author":"Zeng","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbadis.2026.168237_bb0255","article-title":"Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice","volume":"11","author":"Wang","year":"2023","journal-title":"Gastroenterol. Rep."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168237_bb0260","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1096\/fj.202000678R","article-title":"Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD","volume":"34","author":"Weber","year":"2020","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168237_bb0265","first-page":"2477","article-title":"The role and therapeutic implication of CPTs in fatty acid oxidation and cancers progression","volume":"11","author":"Wang","year":"2021","journal-title":"Am. J. Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T20:25:04Z","timestamp":1780172704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0925443926001006"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168237","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic GAL1 deficiency alleviates steatosis via WWP2-mediated PARP1 degradation and activation of the SIRT1\u2013CPT1A pathway","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168237"}}